Boehringer Ingelheim Welcomes Central Role of LAMA/LABA Therapy within 2017 GOLD Strategy for COPD
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - November 16, 2016 Category: Research Source Type: news

Boehringer Ingelheim bevacizumab biosimilar candidate demonstrates bioequivalence to Avastin ®
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - November 15, 2016 Category: Research Source Type: news

Updated Phase III Results Reinforce Safety and Efficacy of Praxbind ® (idarucizumab) in Urgent Situations
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - November 14, 2016 Category: Research Source Type: news

First Data from Boehringer Ingelheim, Anthem and HealthCore Multi-Year Study Show Gaps in Non-valvular Atrial Fibrillation Care
Findings from more than 45,000 NVAF patients show less than half were treated with an oral anticoagulant, including those at highest risk of stroke Data presented at American Heart Association Scientific Sessions will be used to guide future research to help improve patient outcomes (Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - November 13, 2016 Category: Research Source Type: news

Jardiance ® (empagliflozin) consistently reduced the risk of cardiovascular death in adults with type 2 diabetes regardless of the type of cardiovascular disease at baseline
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - November 12, 2016 Category: Research Source Type: news

Boehringer Ingelheim Named One of Science Magazine ’s Top Employers for the Twelfth Consecutive Year
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - October 26, 2016 Category: Research Source Type: news

Boehringer Ingelheim ’s adalimumab biosimilar candidate shows similar efficacy and safety profile to Humira® in pivotal Phase III study
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - October 25, 2016 Category: Research Source Type: news

Efficacy of Ofev ® (nintedanib) Reinforced in Range of Patients with IPF in New Analyses Presented at CHEST
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - October 23, 2016 Category: Research Source Type: news

New Real-World Data Show Pradaxa ® (dabigatran etexilate mesylate) Treatment Resulted in Less Use of All-Cause Healthcare Resources than Warfarin Treatment
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - October 20, 2016 Category: Research Source Type: news

Boehringer Ingelheim joins The Leukemia & Lymphoma Society in groundbreaking precision medicine approach to treating acute myeloid leukemia
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - October 17, 2016 Category: Research Source Type: news

New Data Analyses Provide Insights That May Help Predict COPD Exacerbation Risk
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - October 16, 2016 Category: Research Source Type: news

New Support Program Provides Free Medicine and Resources for People Living with COPD Prescribed STIOLTO ® RESPIMAT® (tiotropium bromide and olodaterol) Inhalation Spray
“STIOLTO Promise” Program Includes Free 30-Days of Medicine and At-Home Counsel from Respiratory Therapist or Nurse (Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - October 11, 2016 Category: Research Source Type: news

Phase III nintedanib trial results in patients with metastatic colorectal cancer announced at ESMO
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - October 8, 2016 Category: Research Source Type: news

Overall survival data from LUX-Lung 7 head-to-head trial of Gilotrif ® (afatinib) versus Iressa® (gefitinib) presented at ESMO
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - October 8, 2016 Category: Research Source Type: news

Researchers Publish Largest Observational Study To-Date Comparing Novel Oral Anticoagulants (NOACs) Pradaxa ® (dabigatran etexilate mesylate) and Rivaroxaban
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - October 5, 2016 Category: Research Source Type: news

Leading Patient and Professional Advocacy Organizations Endorse the 4WARD Coalition Resource to Advance Anticoagulation Care
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - October 3, 2016 Category: Research Source Type: news

Boehringer Ingelheim returns development and commercial rights of olmutinib to Hanmi Pharmaceutical
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - September 29, 2016 Category: Research Source Type: news

Boehringer Ingelheim and Sarah Cannon Research Institute launch strategic collaboration to develop novel immune-oncology therapies
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - September 28, 2016 Category: Research Source Type: news

Boehringer Ingelheim boosts immune-oncology pipeline through collaboration with ViraTherapeutics
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - September 27, 2016 Category: Research Source Type: news

Boehringer Ingelheim Named to the 2016 Working Mother 100 Best Companies List
This is the fifth consecutive year the company has earned this prestigious honor (Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - September 26, 2016 Category: Research Source Type: news

Orphan Drug Designation Granted to Nintedanib for Treatment of Systemic Sclerosis, including Associated Interstitial Lung Disease
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - September 8, 2016 Category: Research Source Type: news

New analysis showed dose adjustment of Gilotrif ® (afatinib) improved tolerability without an apparent impact on efficacy in patients with EGFR mutation-positive non-small cell lung cancer
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - September 7, 2016 Category: Research Source Type: news

New Long-Term Data Demonstrates Continued Safety and Beneficial Effect of Ofev ® (Nintedanib) for Patients with IPF
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - September 6, 2016 Category: Research Source Type: news

Tiotropium RESPIMAT ® Improved Lung Function with Safety Comparable to Placebo in Children with Asthma
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - September 5, 2016 Category: Research Source Type: news

New Data: STIOLTO ® RESPIMAT® (tiotropium bromide+olodaterol) Inhalation Spray Significantly Improved Exercise Capacity in People with COPD
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - September 4, 2016 Category: Research Source Type: news

Simple Blood Test Combined with Exacerbation History May Help to Identify When to Add ICS to COPD Treatment
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - September 4, 2016 Category: Research Source Type: news

Amgen obtains global development and commercial rights from Boehringer Ingelheim for investigational BiTE ® immuno-oncology drug for multiple myeloma
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - August 31, 2016 Category: Research Source Type: news

Qualcomm and Boehringer Ingelheim Pharmaceuticals collaborate to add new digital technology to RESPIMAT ® inhaler
-- Two industry leaders combine strengths in health care and technology to aim to improve chronic obstructive pulmonary disease (COPD) care – (Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - August 29, 2016 Category: Research Source Type: news

ESC Congress 2016 Late Breaking Science Registry: Latest Data on Pradaxa (dabigatran etexilate mesylate) Safety and Effectiveness Profile Show Low Rates of Bleeding and Stroke in NVAF Patients in Routine Clinical Care
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - August 28, 2016 Category: Research Source Type: news

Boehringer Ingelheim and Duke Clinical Research Institute Expand Collaboration to Create Largest Patient Registry for Idiopathic Pulmonary Fibrosis (IPF)
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - August 24, 2016 Category: Research Source Type: news

Boehringer Ingelheim Launches RE-VECTO Global Program to Capture Data on Praxbind ® (idarucizumab) Usage in Clinical Practice
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - August 14, 2016 Category: Research Source Type: news

First Study Initiated to Evaluate the Effect of Ofev ® Treatment on Biomarkers that may Predict IPF Progression
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - July 26, 2016 Category: Research Source Type: news

Boehringer Ingelheim stops LUX-Head & Neck 2 and 4 trials following pre-planned analysis from independent Data Monitoring Committee
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - July 24, 2016 Category: Research Source Type: news

U.S. FDA expands indication for type 2 diabetes treatment Synjardy ® (empagliflozin/metformin hydrochloride) to include treatment-naïve adults
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - July 18, 2016 Category: Research Source Type: news

U.S. FDA expands indication for type 2 diabetes treatment Synjardy® (empagliflozin/metformin hydrochloride) to include treatment-naïve adults
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - July 18, 2016 Category: Research Source Type: news

Boehringer Ingelheim and Lilly Announce Clinical Trial Collaboration in Metastatic Breast Cancer
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - July 12, 2016 Category: Research Source Type: news

FDA Advisory Committee recommends approval of Jardiance ® (empagliflozin) for cardiovascular indication   in 12-11 vote
Endocrinologic and Metabolic Drugs Advisory Committee votes in favor   of CV mortality benefit for JARDIANCE for adults with type 2 diabetes (Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - June 27, 2016 Category: Research Source Type: news

FDA Advisory Committee recommends approval of Jardiance® (empagliflozin) for cardiovascular indication in 12-11 vote
Endocrinologic and Metabolic Drugs Advisory Committee votes in favor of CV mortality benefit for JARDIANCE for adults with type 2 diabetes (Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - June 27, 2016 Category: Research Source Type: news

New analysis of INPULSIS ™ trials demonstrates efficacy of OFEV® (nintedanib) across a range of IPF patients using broader diagnostic criteria
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - June 26, 2016 Category: Research Source Type: news

New analysis of INPULSIS™ trials demonstrates efficacy of OFEV® (nintedanib) across a range of IPF patients using broader diagnostic criteria
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - June 26, 2016 Category: Research Source Type: news

Jardiance ® (empagliflozin) significantly reduced the risk of progressive kidney disease in adults with type 2 diabetes with established cardiovascular disease
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - June 13, 2016 Category: Research Source Type: news

Jardiance® (empagliflozin) significantly reduced the risk of progressive kidney disease in adults with type 2 diabetes with established cardiovascular disease
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - June 13, 2016 Category: Research Source Type: news

New Jardiance ® (empagliflozin) data show that reduced risk for cardiovascular (CV) death was consistent across age groups in adults with type 2 diabetes
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - June 11, 2016 Category: Research Source Type: news

New Jardiance® (empagliflozin) data show that reduced risk for cardiovascular (CV) death was consistent across age groups in adults with type 2 diabetes
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - June 11, 2016 Category: Research Source Type: news

New study results show Tradjenta ® (linagliptin) reduces blood sugar in adults with type 2 diabetes at risk for kidney impairment
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - June 10, 2016 Category: Research Source Type: news

New study results show Tradjenta® (linagliptin) reduces blood sugar in adults with type 2 diabetes at risk for kidney impairment
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - June 10, 2016 Category: Research Source Type: news

Results of Phase III study of volasertib for the treatment of acute myeloid leukemia presented at European Hematology Association Annual Meeting
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - June 10, 2016 Category: Research Source Type: news

Boehringer Ingelheim and Harvard scientists establish a research alliance to find novel treatments for severe fibrotic diseases
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - June 8, 2016 Category: Research Source Type: news

Boehringer Ingelheim and HealthPrize Partner to Launch New Support Program for People Treating COPD With SPIRIVA® RESPIMAT® (tiotropium bromide) Inhalation Spray
People living with chronic obstructive pulmonary disease (COPD) can earn rewards for tracking medication use and learning more about COPD (Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - June 7, 2016 Category: Research Source Type: news

Boehringer Ingelheim and Inventiva collaborate to develop potential new treatments for idiopathic pulmonary fibrosis
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - June 5, 2016 Category: Research Source Type: news